Chiesi Farmaceutici has patented a method for administering oral octreotide to female subjects needing contraception. The method involves a specific oral dosage form and counseling to avoid combined oral contraceptives. GlobalData’s report on Chiesi Farmaceutici gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Chiesi Farmaceutici SpA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Chiesi Farmaceutici, Inhalation devices was a key innovation area identified from patents. Chiesi Farmaceutici's grant share as of February 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

Oral octreotide therapy method for females needing contraception

Source: United States Patent and Trademark Office (USPTO). Credit: Chiesi Farmaceutici SpA

A recently granted patent (Publication Number: US11890316B2) discloses a method for administering oral octreotide to female subjects in need of a contraceptive method. The method involves administering an oral dosage form containing octreotide and a medium chain fatty acid salt, along with counseling the subject to avoid concomitant use of a combined oral contraceptive. The composition comprises 12% to 21% by weight of the medium chain fatty acid salt and is specifically designed for subjects with conditions like acromegaly or severe diarrhea associated with metastatic carcinoid tumor.

Furthermore, the patent also covers a method for administering oral octreotide to female subjects already using a combined oral contraceptive. In this case, the subject is counseled to use a back-up method of contraception or an alternative non-hormonal method. The composition of the oral dosage form remains the same, with the addition of counseling guidelines specific to subjects using combined oral contraceptives, particularly those containing levonorgestrel. The patent details the specific components of the composition, including the medium chain fatty acid salt, polyvinylpyrrolidone (PVP), and the hydrophobic medium, which can include glyceryl tricaprylate or castor oil, among others. The oral dosage form can be in the form of a capsule, which may be enterically coated for optimal delivery.

To know more about GlobalData’s detailed insights on Chiesi Farmaceutici, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies